Domestic pharmaceutical companies have launched an antidepressant Brintellix first generic challenge. According to the pharmaceutical industry on the 16th, Myungin and Unimed filed an application with the MFDS this month to approve generics of Lundbeck Korea Brintellix.

It has been five months since the two companies filed a trial to confirm the invalidity and passive scope of rights of the original patent. In February, the two companies developed and started with BA test approval from the MFDS. This is because pharmaceutical companies that filed the first patent lawsuit at generics and applied for permission can obtain generic for exclusivity. If acquired generic for exclusivity, it can be monopolized